1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 14 MARCH 2016

Cancer Drug News 14 MARCH 2016

  • March 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Towards Harmonising Transatlantic Review Times
Industry Trend Analysis - Zydelig Woes Underscore Need For Scale-Up In Diversification Efforts
Industry Brief - FDA Grants ODD To ProNAi's PNT2258 For DLBCL
Industry Brief - Variation To Arzerra Marketing Authorisation Filed With EMA
Industry Brief - DSMB Recommends Advancing Medigene's DC AML Vaccine To Phase II
Industry Brief - Pfizer's Xalkori Granted FDA Approval For ROS1-Positive Metastatic NSCLC
Industry Brief - Imbruvica FDA-Approved For First-line Treatment Of CLL
Industry Brief - FDA Accepts Keytruda sBLA In Advanced NSCLC
Industry Brief - FDA ODD For Soricimed's SOR-C13 To Treat Ovarian Cancer
Industry Brief - XBiotech Submits Xilonix MAA In EU To Treat Advance CRC
Industry Brief - DSMB Recommends Discontinuation Of Celldex' Rintega Phase III Study In Glioblastoma
Industry Brief - Lenvima Launched In Israel To Treat Advanced Thyroid Cancer
Industry Trend Analysis - USD999 Whole Genome Sequencing Will Challenge Single Biomarker Tests
Industry Trend Analysis - Growing Cancer Burden Will Boost Revenue Earning Opportunities
Industry Brief - Aprea Completes Fundraising To Advance APR-246 Clinical Development
Industry Brief - Aspyrian Secures Series B Funding

Table Of Contents

Cancer Drug News 14 MARCH 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.